Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis

Table 2

FVC, TLC, DL_CO, 6MWD, and P_A-aO₂ at baseline and 6 and 12 month after MMF treatment.

	Baseline	6 months	12 months	𝑃-value^1	𝑃-value^2
FVC (%) pred	59.2 ± 17.1	58.2 ± 17.2	55 ± 14.9	0.228	0.081
TLC (%)	53.9 +10.2	53.6 +12.3	52 ±12.8	0.702	0.081
DLCO (%)	39.4 + 9.3	38.5 + 9	35.2 + 8.8	0.47	0.053
6MWD	441 +124	NA	421 + 123	NA	0.09
PA-aO2	27.4 +11.5	NA	27.7+11.2	NA	0.67

Data are presented as mean ± SD unless stated otherwise, 𝑃-value¹: between baseline and 6 months, 𝑃-value²: between baseline and 12 months;
6MWD: 6-minute walking distance, FVC: forced vital capacity, NA: nonapplicable, P_A-aO₂: alveolar-arterial gradient of oxygen tension, TLC: total lung capacity.